I am baffled why you seem to be fixating on the MAbs here. MAbs aren't important here. The interaction and the inhibition thereof is.
I don't even understand what you mean here
Cytotoxic therapy agents are, surprisingly, cytotoxic. You might not have enough contact with them for them to kill you, but it's not for lack of trying. They wouldn't be terribly good at their job if they weren't.
Once again, *everything* is toxic in the right amounts. You're making a difference where there is none. If you're killed by the side effects it matters little whether we are talking about a monoclonal antibody, a cytotoxic agent of whatever sort (because it's not like they're a homogeneous class), or whatever else.
You seem to be operating under the notion I'm against chemo - I am not, by no means! But I am emphatically for developing something better, because there has to be a more optimal primary approach to eliminating neoplasms than 'kill them all and let proliferation rates sort them out'. Especially since cancer cells are pretty damn good at dodging those and coming back in force.
Once again, the matter is far more complex than mabs being "better" than chemotherapy. You are fixated in "less side effects = better", which isn't necessarily true (and it's not necessarily true that they have less side effects either. Have you checked nivolumab's tech profile? It's pretty nasty. Likely less nasty than taxanes, true, but it's not something that you can casually say "oh, it's not toxic" either)
Hell, it's not like this isn't an ongoing debate with nivolumab right now :
http://www.esmo.org/Conferences/ESMO-2016-Congress/Press-Media/Greater-Patient-Selection-May-be-Needed-for-First-Line-Nivolumab-to-Improve-Progression-free-Survival-in-Advanced-Lung-Cancer
(Full disclosure, second from top is a source from the manufacturer.)
Well shit, science advances. New treatments appear that have better results. Who would have known?
Except that STILL doesn't mean that standard chemotherapy is out of the picture with the appaerance of mabs. What that trial says is that in relapsed NSCLC nivolumab is superior to docetaxel
in monotherapy. (worth noting that in both cases it's still fairly lousy. As you might expect from a refractory tumor, on the other hand)
But if you check what's going on currently with nivolumab, you find that, surprise surprise, current trials are testing it in combination with other mAbs or with chemotherapy:
https://clinicaltrials.gov/ct2/show/NCT02477826http://www.ascopost.com/issues/july-10-2016/combination-of-nivolumab-and-ipilimumab-moves-forward-in-nsclc/So, no, I'm not denying the effectiveness of new therapies. I'm denying a fact that you seem to be persistently oblivious to: They don't debunk conventional, and a good deal of work is underway to combine them with conventional therapies.
It's not like there's no precedent. There are quite a few mAbs that have been in the market for years (most notably rituximab), and for the most part they're used in combination therapy.
By the way, there's a solid, known, biological reason for this. Monoclonal antibodies, as the name suggests, have one single target. Therefore you're selecting for clones that don't express said target, thus encountering eventual resistance if used in monotherapy. Now, I'm guessing this occurs faster in haematological tumors because of them having (for the most part) a higher Ki67, but common sense (and a fast check on the literature) suggests that the same principle applies.